Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin kidney oxygenation study in diabetic kidney disease
ChiCTR2000036701Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of empagliflozin in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Huashan Hospital. Primary endpoint: Kidney oxygenation index. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2000036701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036701.